Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar sponsors can avoid 'patent dance' in US, but innovators win extra exclusivity

This article was originally published in SRA

Executive Summary

Biosimilar sponsors won a partial victory in the battle over the meaning of the US biosimilars statute as an appeals court found that the patent exchange process laid out in the law is optional1. But avoiding the disclosure and negotiation procedures or 'patent dance' in the Biologics Price Competition and Innovation Act opens them up to litigation over a larger number of patents, which could be problematic for biosimilars of newer biologics.

You may also be interested in...



Amgen v. Sandoz: Next Biosimilar Bout Begins Over State Law Claims

In the ongoing Zarxio dispute, US appeals court takes up question left open by Supreme Court as to whether innovator company can seek remedy under state law if a biosimilar sponsor does not engage in the "patent dance" by providing its application and manufacturing information.

Amgen v. Sandoz: Next Biosimilar Bout Begins Over State Law Claims

In the ongoing Zarxio dispute, US appeals court takes up question left open by Supreme Court as to whether innovator company can seek remedy under state law if a biosimilar sponsor does not engage in the "patent dance" by providing its application and manufacturing information.

FDA's Worst Case Scenario: Supreme Court Might Defer To It On Biosimilars

During oral arguments in Sandoz v Amgen, justices suggest FDA issue rule-making on whether biosimilar sponsors can give early notification of launches and need to follow all the steps in the patent dance. The agency has explicitly said it wants to be left out of it.

Related Content

UsernamePublicRestriction

Register

PS118314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel